United States

Abstract Title
Propofol-Induced Cannabinoid Hyperemesis Syndrome in a Chronic Cannabis User

Background

Cannabinoid Hyperemesis Syndrome (CHS) is a paradoxical condition in chronic cannabis users characterized by cyclic nausea and vomiting, despite cannabis&#39;s known antiemetic effects. Propofol-induced Cannabinoid Hyperemesis Syndrome (PI-CHS) is an emerging, under-recognized phenomenon in which propofol anesthesia may trigger CHS-like symptoms in chronic cannabis users. The suspected mechanism involves propofol’s lipophilic nature mobilizing stored delta-9-tetrahydrocannabinol (THC) from adipose tissue, potentially precipitating an acute emetic response.

Case Presentation

A 56-year-old male presented at the stand-alone surgical center for a routine screening colonoscopy. He reported daily cannabis use for over 40 years, with no history of chronic illness, alcohol, or tobacco use. His previous colonoscopy, performed six years prior, was followed by severe nausea and vomiting, which he attributed to an unknown cause at the time. Preoperative evaluation was otherwise unremarkable. He denied baseline gastrointestinal symptoms, cyclic vomiting, or any personal or family history of anesthesia complications. Following the current colonoscopy, which was performed under propofol sedation, the patient again developed intractable nausea and vomiting within hours post-procedure, necessitating emergency department evaluation. Workup revealed no surgical or infectious cause. Supportive care and cessation of cannabis use led to resolution of symptoms over several days.

Discussion

This case highlights a potential association between propofol administration and the unmasking of CHS in chronic cannabis users. The theory that propofol may mobilize THC from fat stores into circulation offers a possible mechanism for PI-CHS. As cannabis use continues to rise, anesthesiologists and perioperative providers should be aware of this phenomenon. Preoperative screening for chronic cannabis use may help identify at-risk patients and guide perioperative planning. Further studies are needed to elucidate the pathophysiology of PI-CHS and to establish appropriate prevention and management strategies.


2025 AMA Research Challenge – Member Premier Access

Propofol-Induced Cannabinoid Hyperemesis Syndrome in a Chronic Cannabis User: A Case Report

Abstract Title
Propofol-Induced Cannabinoid Hyperemesis Syndrome in a Chronic Cannabis User

Background

Cannabinoid Hyperemesis Syndrome (CHS) is a paradoxical condition in chronic cannabis users characterized by cyclic nausea and vomiting, despite cannabis's known antiemetic effects. Propofol-induced Cannabinoid Hyperemesis Syndrome (PI-CHS) is an emerging, under-recognized phenomenon in which propofol anesthesia may trigger CHS-like symptoms in chronic cannabis users. The suspected mechanism involves propofol’s lipophilic nature mobilizing stored delta-9-tetrahydrocannabinol (THC) from adipose tissue, potentially precipitating an acute emetic response.

Case Presentation

A 56-year-old male presented at the stand-alone surgical center for a routine screening colonoscopy. He reported daily cannabis use for over 40 years, with no history of chronic illness, alcohol, or tobacco use. His previous colonoscopy, performed six years prior, was followed by severe nausea and vomiting, which he attributed to an unknown cause at the time. Preoperative evaluation was otherwise unremarkable. He denied baseline gastrointestinal symptoms, cyclic vomiting, or any personal or family history of anesthesia complications. Following the current colonoscopy, which was performed under propofol sedation, the patient again developed intractable nausea and vomiting within hours post-procedure, necessitating emergency department evaluation. Workup revealed no surgical or infectious cause. Supportive care and cessation of cannabis use led to resolution of symptoms over several days.

Discussion

This case highlights a potential association between propofol administration and the unmasking of CHS in chronic cannabis users. The theory that propofol may mobilize THC from fat stores into circulation offers a possible mechanism for PI-CHS. As cannabis use continues to rise, anesthesiologists and perioperative providers should be aware of this phenomenon. Preoperative screening for chronic cannabis use may help identify at-risk patients and guide perioperative planning. Further studies are needed to elucidate the pathophysiology of PI-CHS and to establish appropriate prevention and management strategies.


poster

Congratulations to all the researchers who have qualified for the AMA Research Challenge virtual poster symposium and semifinals!

Welcome to the **largest national, multi-specialty research event** featuring research from nearly 1,000 medical students, residents, fellows, and international medical graduates across six topic areas - basic science, clinical and translational research, clinical vignettes, health systems science, medical education, and public health and health policy.

#### Access the Event
Use the buttons below or navigation menu to access the event. 

[![](https://assets.underline.io/markdown_image/1/image/d4076f2146939317a29eb9f69c53ad41.png)](https://underline.io/events/506/sessions?searchGroup=all)
[![](https://assets.underline.io/markdown_image/1/image/6bcee0b523a4874c4292ca0415d88dde.png)](https://underline.io/events/506/posters?searchGroup=all)
[![](https://assets.underline.io/markdown_image/1/image/0ca1b933deefd7731529477b45345166.png)](https://underline.io/events/506/schedule)

#### Event Details
The 2025 AMA Research Challenge includes the following symposium halls:
* **Semifinals hall:** Features research from 54 medical students, residents and international medical graduates that received top scores during first round scoring. 
* **Poster symposium hall:** Features research from nearly 1,000 medical students, residents and international medical graduates categorized by topics and subtopics.

**Here’s how to participate:**
* **View posters and presentations** on a variety of topics and specialties
* **Score posters in the semifinals** to help decide the top five finalists (AMA member exclusive opportunity)
* **Connect with presenters** and provide feedback to help advance their research
* **New this year: Watch live poster presentations** by topic area and engage directly with researchers

At the conclusion of this event, the AMA will announce the top five finalists who will advance to the AMA Research Challenge final round, present their research to an elite panel of judges, and compete to win a $10,000 grand prize presented by Laurel Road.

#### A message from Dr. Bobby Mukkamala, AMA President
<div style="position: relative; width: 100%; padding-bottom: 56.25%; height: 0; overflow: hidden;">
  <iframe 
    src="https://underline.io/embed/136894-ama-video?t=0"
    title="AMA Welcome Video"
    allowfullscreen
    style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 0;">
  </iframe>
</div>


#### Recognized Institutions
In 2025, 1,400 abstracts were submitted across six topic areas representing 174 medical schools and more than 150 residency and health care institutions. [See if your institution is represented this year!](https://drive.google.com/file/d/1eFrTqCmCeobx9pr5drJK2hllvsIpFNOY/view?usp=drive_link)

#### Grand Prize Sponsor
AMA would like to thank Laurel Road, a brand of KeyBank, for sponsoring a $10,000 grand prize for the winner of the AMA Research Challenge. Laurel Road and KeyBank are not involved in winner selection process. The winner will be announced during the AMA Research Challenge final round. Payment of the grand prize will be directly from Laurel Road/KeyBank. See the [AMA Research Challenge Official Rules for terms and conditions](https://www.ama-assn.org/system/files/research-challenge-official-rules.pdf).

[![](https://assets.underline.io/uploads/markdown_image/1/image/611e331d4a0eba0920f240cfc04b4d77.png)](https://www.laurelroad.com/)

#### Code of Conduct
<html>
AMA has a code of conduct for its meetings – we ask all attendees to adhere to this code to participate in this year’s meeting. Please read and <a href="https://www.ama-assn.org/about/code-conduct" target="_blank">learn more here</a> about your conduct requirements.
<br><br>
	</html>
	

#### Semifinals Judges

You need to log in with the email address you registered with. Access credentials have been sent to your email. 

Please be sure to check your spam and other email folders if you do not see an email confirmation right away.

Need help? Contact us at <support@underline.io>.

Please log in to explore this event.

If you have used the AMA Research Challenge platform previously, please click the ‘Log-in’ button below. If you do not remember your password, please click “forgot password” and follow prompts to reset your password. After resetting your password, please refresh your webpage to access the platform. 

Register to explore research in a variety of topics. AMA members get exclusive access to score posters in the semifinals. 

**Please use [this link here](https://www.ama-assn.org/member-benefits/events/ama-research-challenge) to register for free. **

Registration Is Required

Join the AMA Research Challenge poster symposium and semifinals to explore top research posters and score posters in the semifinals (an AMA member exclusive opportunity).

Background: Prostate cancer (PC) growth is driven by androgen receptor (AR) signaling, and AR-targeted therapies extend survival in many patients. However, advanced tumors develop resistance to these therapies via various mechanisms like adopting basal-like or stem cell–like (SCL) transcriptional programs, which are less dependent on AR and linked to aggressive, treatment-resistant disease. As 30-40% of PCs are basal-like, identifying underlying mechanisms in which these PCs become basal or SCL is vital for treating aggressive PCs. CREB5, a transcription factor, has been implicated in the progression of breast, colorectal, and prostate cancers. However, while these studies independently point to CREB5 as a key factor of tumor progression, the underlying transcriptional regulatory role of CREB5 in PC remains elusive.

Methods:
We analyzed RNA-sequencing data from 701 patient tumors (n=208, Stand Up To Cancer; n=493, TCGA) to assess correlations between CREB5 expression, AR activity, and basal and SCL gene signatures. In an AR-positive PC cell line (LNCaP), rapid immunoprecipitation mass spectrometry of endogenous protein (RIME) and chromatin immunoprecipitation (ChIP) assays determined CREB5’s protein interactions and its binding to regulatory DNA elements. Functional impact on tumor progression was evaluated by measuring three-dimensional tumorsphere formation in vitro, and assessing tumor growth in mouse xenografts with CREB5 overexpressed in the LNCaP cell line.

Results:
High CREB5 expression inversely correlated with AR signaling and positively correlated with basal-like and SCL transcriptional programs in both primary and castration-resistant PCs. We found that CREB5 protein interacted with AP-1 factors, which have previously been implicated in stem cell features, therapy resistance, and metastasis. CREB5 also bound to regulatory elements of several AP-1 factors,  suggesting a complex mechanistic role in regulating activity of numerous AP-1 genes. Functionally, cells overexpressing CREB5 formed significantly more tumorspheres and produced larger tumors in vivo, demonstrating its association with enhanced stemness and aggressive growth in PC.

Conclusion:
Altogether, this study indicates that CREB5 enhances PC tumor progression through genes that are associated with SCL transcriptional programs. Therefore, CREB5 may act as a pivotal regulator of differentiation in PC. As CREB5 was associated with AP-1 family members, this may be a mechanism of such tumor progression. Altogether, increased CREB5 may lead to specific mechanisms of therapy response, and future therapeutic strategies may consider antagonizing CREB5 interactions with AP-1 complexes to mitigate tumor progression in deadly PCs.

CREB5 Regulates Stem Cell-like Transcriptional Programs to Boost Tumor Formation in Prostate Cancer

Title- Intravascular Lithotripsy as a Facilitator for Stenting in Heavily Calcified Subclavian Artery Lesions: A Clinical Case Report

Background- Subclavian artery stenosis is a rare but clinically significant cause of
vertebrobasilar insufficiency and upper extremity ischemia. Management is challenging, especially in the presence of heavily calcified lesions. Intravascular lithotripsy (IVL) is an emerging adjunctive therapy for calcified lesions, primarily studied in coronary and lower extremity vessels; however, its application in subclavian interventions remains minimally studied.

Case Presentation- A 78-year-old female with a history of hypertension, diabetes,
Hyperlipidemia and peripheral artery disease presented with recurrent dizziness and nausea. Carotid duplex demonstrated moderate left internal carotid stenosis and retrograde flow in the left vertebral artery, consistent with subclavian steal syndrome. Subsequent angiography revealed 90% eccentric, calcified stenosis of the proximal left subclavian artery. Given the lesion’s heavy calcification, the patient underwent percutaneous intervention with a Serranator scoring balloon, followed by intravascular lithotripsy (IVL) using an 8x30 mm peripheral balloon (2 rounds, 30 pulses each). This resulted in significant lesion modification and relief of the balloon waist. A 7x27 mm Express LD bare-metal stent was then deployed with excellent angiographic results and residual stenosis <10%. IVUS confirmed adequate stent expansion. The procedure was performed via right femoral access with no complications. Post-procedure, the patient reported complete resolution of dizziness and no further symptoms of vertebrobasilar insufficiency. She was discharged on dual antiplatelet therapy for 30 days, followed by aspirin monotherapy. At 1-month follow-up, she remained asymptomatic with a patent stent and no evidence of restenosis.

Discussion- This case highlights the utility of IVL in treating severely calcified subclavian artery stenosis. Traditional balloon angioplasty and stenting in such lesions are associated with suboptimal expansion, risk of dissection, and restenosis. IVL offers a safe and effective means of calcium modification, facilitating optimal stent deployment. To our knowledge, reports of IVL use in subclavian arteries are scarce, and this case adds to the growing body of evidence supporting its application in complex peripheral vascular interventions. Intravascular lithotripsy is a valuable adjunct in the endovascular management of heavily calcified subclavian artery stenosis, enabling successful stent placement and symptomatic relief. Further studies are warranted to define its role in this vascular territory.

Intravascular Lithotripsy as a Facilitator for Stenting in Heavily Calcified
Subclavian Artery Lesions: A Clinical Case Report

Background: Intentional drug overdose remains a pressing public health issue, with calcium channel blockers (CCBs) frequently involved due to their widespread use in the treatment of hypertension and cardiovascular conditions. CCB toxicity can be particularly lethal, as inhibition of L-type calcium channels may result in severe bradycardia, hypotension, cardiogenic shock, and death. Prompt and aggressive intervention is critical, with emerging evidence supporting advanced therapies such as extracorporeal membrane oxygenation (ECMO) and intravenous lipid emulsion in cases of refractory toxicity. Effective management becomes even more challenging in rural or critical access hospitals (CAHs), where limited resources can delay access to life-saving interventions.

Case Presentation: We report the case of a 15-year-old male who presented to a CAH following intentional ingestion of over 100 pills, including verapamil, sertraline, risperidone, gabapentin, and levetiracetam. Initially stable, the patient rapidly deteriorated, experiencing seizures, unresponsiveness, and hypotension. He was emergently intubated and received activated charcoal, IV fluids, magnesium, norepinephrine, and empiric antibiotics. Despite aggressive stabilization efforts, refractory hypotension persisted, prompting urgent transfer to a quaternary care center. There, he required multiple vasopressors and initiation of veno-arterial ECMO. Hyperinsulinemic euglycemia therapy was also administered. After three days on ECMO and a prolonged ICU course, the patient made a full neurologic recovery and was discharged home on hospital day 11.

Discussion: This case underscores the challenges of managing complex toxicologic emergencies in resource-limited rural settings. Polypharmacy ingestion involving a high-potency CCB like verapamil increases the risk of rapid hemodynamic collapse. Early recognition and prompt stabilization at the CAH enabled safe transfer, demonstrating that favorable outcomes are possible with coordinated care. High-dose insulin therapy and ECMO remain the cornerstone interventions for severe CCB toxicity, especially when conventional therapies fail. Notably, this is only the second pediatric case of CCB overdose reported in the literature to result in full recovery; the first involved acute kidney injury. Our case illustrates the importance of prehospital triage protocols and equitable access to advanced resuscitative therapies like ECMO, even in rural populations.


Pediatric Calcium Channel Blocker Polypharmacy Overdose in a Resource-Limited Emergency Department: Full Recovery After ECMO


Background
Emphysematous pyelonephritis (EPN) is a life-threatening necrotizing infection of the renal parenchyma and surrounding tissues. It is most commonly seen in patients with uncontrolled diabetes and obstructive uropathy. Rapid diagnosis and timely radiologic intervention are essential to prevent progression to sepsis or death.

Case Presentation
A 67-year-old woman with poorly controlled diabetes and recent history of nephrolithiasis presented to the emergency department with fever, chills, altered mental status, and right flank pain. She was febrile, hypotensive, and tachycardic on arrival. Laboratory studies showed leukocytosis, acute kidney injury, and hyperglycemia. Urinalysis revealed pyuria and bacteriuria.
Initial ultrasound showed a markedly echogenic right kidney with poor corticomedullary differentiation and dirty shadowing, raising concern for gas formation. Non-contrast CT confirmed the diagnosis of emphysematous pyelonephritis, demonstrating parenchymal destruction and extensive gas within the renal collecting system and perinephric space.
Given the patient’s instability and imaging findings, she was admitted to the ICU and started on broad-spectrum IV antibiotics. Urology was consulted, and interventional radiology performed emergent image-guided percutaneous nephrostomy and drainage catheter placement. Cultures grew E. coli. Over the following days, the patient’s hemodynamics improved, and nephrectomy was avoided.

Discussion
This case highlights the importance of early imaging in patients with sepsis and risk factors for EPN, such as diabetes and obstructive uropathy. Although nephrectomy has historically been the treatment of choice, image-guided drainage has emerged as a kidney-sparing alternative, particularly in critically ill patients. Ultrasound can provide initial clues, but CT is the diagnostic gold standard. Multidisciplinary collaboration between critical care, urology, and interventional radiology is essential for optimal outcomes.

Emphysematous Pyelonephritis in a Critically Ill Patient: Prompt Diagnosis and Image-Guided Drainage to Avoid Nephrectomy


Background: 
Kawasaki Disease (KD) is an acute, self-limited medium vessel vasculitis of unknown etiology that is the leading cause of acquired heart disease in children in developed countries. Kawasaki disease primarily affects infants and young children, primarily those under the age of 5 years old. The odds of recurrences after the fifth year following recurrence are 4%. We present a case of recurrent KD presenting 8 years following the patient's initial diagnosis at 4 months. 
Case Presentation: 
An 8-year-old male patient with a history of Kawasaki Disease at 4 months presented initially to the ED with 6 days of fever, malaise, bilateral conjunctival injection and one day of bilateral joint pain. There was a recent history of mild viral illness among household contacts. On examination, bilateral erythema of the hands and feet were also noted. The patient also presented with bilateral testicles visualized in the superior inguinal canal on ultrasound. Upon admission, crusting of the oral mucosa, bilateral joint effusion, and unilateral cervical lymphadenopathy were also noted. An echocardiogram demonstrated a mildly distended left anterior descending artery. The patient was diagnosed with KD and subsequently treated with aspirin 325 mg four times a day, IVIG, and methylprednisolone 30 mg twice a day. The patient then experienced significant improvement in appetite, appearance, and decreased neck, joint, and eye pain over the next three days. However, the patient was only followed up 17 days later by pediatrics with no cardiology or urology follow-up 6 months after discharge. 
Discussion: 
In patients whose initial KD occurred at a younger age, there is an increased risk of recurrence. Patients less than <6 months and >9 years old are at an increased risk for diagnosis taking over 12 days. While this patient was quickly treated, delayed diagnosis of KD can result in treatment resistance due to the clinical progression of the disease. KD should be considered in the setting of prolonged fever even at extreme ages of presentation. Furthermore, this case highlights the need for cardiac follow-up for patients with recurrent KD, especially in the setting of recurrence where cardiovascular consequences can be devastating. Those who are >6 years of age are at an increased risk for cardiovascular sequelae compared to those <3 years of age. Thus, the suspicion of cardiac complications must remain high after discharge, and adequate follow-up should be established prior to discharge.

A Case of Kawasaki Disease Recurring 8 years later with Cardiac Complications

Dominic Theodore, MS; Nita Bhatt, MD, MPH Department of Psychiatry, Boonshoft School of Medicine, Wright State University
Background
Cochlear implants are widely used to restore hearing in individuals with severe sensorineural hearing loss. However, their placement in individuals with psychotic disorders presents unique challenges. Historically, psychosis was considered a contraindication to cochlear implantation due to concerns about exacerbating hallucinations and delusions. While research suggests that cochlear implants can improve quality of life, there remains a lack of formal guidelines for their use in individuals with schizophrenia or high-risk psychotic disorders. This case highlights the complex interplay between auditory rehabilitation and psychiatric symptomatology.
Case Presentation
A 47-year-old male with schizophrenia and post-traumatic stress disorder (PTSD) was admitted for competency restoration following legal issues related to delusional beliefs and impaired judgment. His psychiatric history included multiple hospitalizations and persistent auditory hallucinations. He had profound hearing loss secondary to childhood encephalitis, with a cochlear implant placed in 2015. Upon admission, the patient exhibited disorganized thoughts, paranoia, and auditory hallucinations directly involving his cochlear implant. He reported experiencing command hallucinations perceived as broadcasts through the device, as well as delusions that it had been modified into a "Neurolink" system to control his thoughts.
During hospitalization, the patient was treated with olanzapine and haloperidol, leading to some improvement in disorganized behavior and hallucinations. However, paranoid delusions related to surveillance and external control persisted. His case underscores the difficulty in distinguishing auditory hallucinations from implant-related perceptual experiences, further complicating treatment and competency restoration efforts.
Discussion
This case highlights the complexities of treating psychosis in individuals with cochlear implants. While hearing restoration can reduce the social isolation that exacerbates psychosis, it may also introduce distressing experiences in patients predisposed to paranoia or delusions. The absence of formal guidelines for screening or managing psychotic symptoms in cochlear implant candidates raises ethical and clinical concerns. Prior research suggests that cochlear implants are not an absolute contraindication in psychosis, yet careful consideration must be given to patient selection and psychiatric stability. Future research and standardized protocols are needed to optimize care for this unique patient population and to balance the benefits of auditory rehabilitation with the risks of exacerbating psychotic symptoms.

Development of Psychotic Symptoms Involving a Cochlear Implant

BACKGROUND Concurrent infective endocarditis (IE) and end-stage liver disease present significant perioperative challenges due to overlapping clinical risks.
CASE SUMMARY A 53-year-old man presented with decompensated cirrhosis and IE characterized by severe aortic regurgitation and vegetation extending into the aortomitral curtain. He underwent a complex, yet successful, simultaneous orthotopic liver transplantation and cardiac surgery, which included double valve replacement and reconstruction of the aortomitral curtain using a patch repair.
DISCUSSION Simultaneous cardiac and liver surgery is rarely performed because of overlapping risks of morbidity. This case illustrates the feasibility and potential benefit of a multidisciplinary, single-stage approach in select high-risk
patients.
TAKE-HOME MESSAGE Concurrent orthotopic liver transplant surgery and double valve replacement with aortic-mitral curtain patch reconstruction for IE can be feasible in very select cases, with successful outcomes hinging on close
multidisciplinary collaborations.

Simultaneous cardiac surgery for infective endocarditis and liver transplantation in end stage liver disease

Background
Gender differences in academic medicine are well established globally, including underrepresentation and decreased scholarly influence among women authors. In ophthalmology, previous research has demonstrated that women publish fewer articles and garner fewer citations than men. Yet, few investigations have specifically investigated gender authorship trends in the highest impact ophthalmology journals, or contrasted these findings with the gender composition of practicing U.S. ophthalmologists. Elucidating these patterns is critical to determining disparities.
Methods
Two leading ophthalmology journals, Ophthalmology and JAMA Ophthalmology, were analyzed for authorship trends. Original research articles published from 2019 to 2023 were reviewed. Authorship order was examined by gender for first, second, and last authors (n=11,801 authors, 1,098 articles). A chi-square test was used to assess gender differences across years. The difference between the percentage of authors and the percentage of physicians in the workforce was calculated using a one-sample proportion test with all percentages acquired from the AAMC US Physician Workforce Data Dashboard. Yearly authorship differences between the years were calculated using analysis of variance, and trends were analyzed with linear regression.
Results
In both journals, significant gender differences were observed in first, second, and last authorship (p<0.001). For Ophthalmology, females comprised 35.82%, 39.21%, and 28.21% of the first, second, and last authors respectively, while in JAMA Ophthalmology, females made up 39.75%, 42.47%, and 33.06% of the same. Compared to the 2022 U.S. ophthalmology workforce, where women comprised 28% of practicing physicians, female authors were 
significantly overrepresented as first and second authors across both journals (p<0.001). No significant yearly authorship differences were found, but there was a downward trend in female second authorship (p=0.04). 
Conclusion
Women continue to be underrepresented in the population of ophthalmologists in the United States. This disparity is apparent in the gender differences observed in two of the leading ophthalmology journals. However, authorship analyses in these journals show that women are overrepresented as first and second authors. Further research is warranted to explore contributing factors such as differences in productivity, mentorship opportunities, or greater pressure to establish scholarly credibility.


Beyond the Lens: Examining Gender Gaps in Ophthalmology Research Authorship

Background
Imposter Phenomenon (IP) is the experience of self-doubt in one’s own abilities and failure to internalize success despite achievements. Originally described by Suzanne Imes and Pauline Rose Clance as they observed successful women in the 1970s, the term has since expanded to all individuals who minimize their achievements and perceive their abilities as frauds. This is a common phenomenon seen in the healthcare field, particularly among medical students, affecting their academic performance and leading to burnout. While there are various factors that contribute to the development of self-undermining behavior, one proposed factor is Adverse Childhood Experiences (ACE), which refers to the negative childhood experiences that can have a lasting impact on a person later in life. While there is much research conducted on ACE and IP separately, there are few studies that link the two subjects, and no study has focused on the population of medical students.

Methods
We conducted a 30-question survey-based study that included demographic questions and validated questionnaires assessing IP and ACE. The ACE questionnaire was developed by the U.S. Centers for Disease Control and Prevention and Kaiser Permanente and the Clance IP questionnaire was created by Clance. The survey was distributed to first- and second-year medical students at Burrell COM. Based on a total population of 391 students, the ideal sample size was calculated to be 78 participants.

Results
We collected a total of 103 surveys. The demographic data showed that the majority of the respondents were between the ages of 20 and 35, identified as Caucasian, and identified as female. The ACE and IP scores were analyzed using the paired t-test. It showed a p-value of < 0.01 and a correlation coefficient (R) value of 0.221.

Conclusion
There is a statistically significant relationship between higher ACE scores and higher Clance IP scores in first- and second-year medical students at Burrell COM, although the positive correlation is weak. This result suggests that the adverse experiences from childhood may influence the psychological well-being of medical students. However, our research was limited due to the small sample size and the use of a single institutional population, limiting the generalizability. Further research needs to be done to identify additional contributing factors to IP. We hope this study can contribute to identifying the roots of medical student burnout and encourage more support for their mental health throughout medical training.

Determining the Correlation Between Adverse Childhood Experiences (ACE) and Imposter Phenomenon (IP) Experienced in Medical Students from Burrell College of Osteopathic Medicine

Background:
Physician involvement in advocacy and health policy is crucial for advancing patient care, population health, and increased access to equitable care. Medical students and trainees often do not receive formal training or accessible resources to learn about the legislative process and to take action. To address this gap, we have created a guide to help medical students and other trainees learn about the legislative process and how to testify at the Rhode Island State House.

Program Description: 
The Rhode Island Health Advocacy and Testimony Guide is a student-made resource created to provide medical students and other medical trainees with a basic understanding of the Rhode Island legislative process. It contains information on how to engage with the State House through written and verbal testimony and how to follow the outcomes of the bills that trainees testify on through time.

Discussion: 
The guide strives to increase student engagement with testimony at the Rhode Island State House, to increase student knowledge about the process of tracking bills as they develop through the Rhode Island legislature, as well as to increase student and trainee confidence with providing written and verbal testimony. This resource will hopefully increase the amount of trainees that testify at the State House as well as to increase discussion of bills being heard and the implications that those bills have on patient care.

Future Directions: 
Future directions of this project include evaluating student confidence in providing testimony, integrating more bill advocacy education into the medical student curriculum, as well as adapting the resource for other medical schools to be able to use as a model.

Next from 2025 AMA Research Challenge – Member Premier Access

CREB5 Regulates Stem Cell-like Transcriptional Programs to Boost Tumor Formation in Prostate Cancer